| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Analysts' ratings for Molina Healthcare (NYSE:MOH) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 4 | 10 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 1 | 2 | 7 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $238.0, with a high estimate of $364.00 and a low estimate of $179.00. This current average represents a 22.89% decrease from the previous average price target of $308.64.
The perception of Molina Healthcare by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Mok | Barclays | Lowers | Equal-Weight | $185.00 | $186.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $210.00 | $210.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $198.00 | $216.00 |
| John Stansel | JP Morgan | Lowers | Neutral | $184.00 | $272.00 |
| Kevin Caliendo | UBS | Lowers | Neutral | $180.00 | $260.00 |
| David Macdonald | Truist Securities | Lowers | Hold | $180.00 | $335.00 |
| Andrew Mok | Barclays | Lowers | Equal-Weight | $186.00 | $270.00 |
| Sarah James | Cantor Fitzgerald | Lowers | Neutral | $210.00 | $312.00 |
| Michael Ha | Baird | Lowers | Neutral | $179.00 | $373.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $216.00 | $372.00 |
| David Macdonald | Truist Securities | Lowers | Buy | $335.00 | $400.00 |
| Ann Hynes | Mizuho | Lowers | Outperform | $330.00 | $400.00 |
| Erin Wright | Morgan Stanley | Lowers | Equal-Weight | $266.00 | $364.00 |
| Andrew Mok | Barclays | Lowers | Equal-Weight | $347.00 | $351.00 |
| Erin Wright | Morgan Stanley | Announces | Overweight | $364.00 | - |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Molina Healthcare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Molina Healthcare analyst ratings.
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Molina Healthcare's remarkable performance in 3M is evident. As of 30 June, 2025, the company achieved an impressive revenue growth rate of 15.66%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 2.23%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Molina Healthcare's ROE excels beyond industry benchmarks, reaching 5.72%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Molina Healthcare's ROA excels beyond industry benchmarks, reaching 1.56%. This signifies efficient management of assets and strong financial health.
Debt Management: Molina Healthcare's debt-to-equity ratio is below the industry average. With a ratio of 0.77, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MOH
